Peptides for sleep: twenty-eight compounds, three mechanism families, one honest evidence map.
Sleep peptide research occupies an awkward position in the peptide landscape: it has a namesake molecule — DSIP, the delta-sleep-inducing peptide — first characterised in 1977, still without a definitive primary receptor, and still without a single published Phase III trial fifty years later. Meanwhile, compounds from adjacent categories produce measurable changes to sleep architecture as secondary effects of their primary pharmacology. This pillar maps twenty-eight spokes across three mechanistic families, grades evidence honestly, and explains where the marketing narrative outpaces the data.
- This is the weakest-evidence cluster on PeptideRadar. The only published human sleep data that would satisfy Western regulatory standards are the MK-677/GH-secretagogue sleep studies from the 1990s.
- DSIP (delta-sleep-inducing peptide) is the category namesake. Discovery paper: Schoenenberger & Monnier, PNAS 1977. Modern mechanistic understanding remains incomplete; no Phase III programme has ever run in the US or EU.
- MK-677 (ibutamoren) has the strongest sleep evidence: Copinschi et al. (1997) showed increased slow-wave and REM sleep in normal adults. The mechanism is GH-pulse amplification → slow-wave sleep coupling, not a primary sleep-receptor effect.
- Epitalon's circadian evidence originates predominantly from the Khavinson group at the St. Petersburg Institute of Bioregulation. Independent Western replication is absent. Claims about melatonin normalisation should be read with that proviso explicitly in mind.
- Selank and CJC-1295/Ipamorelin affect sleep indirectly — anxiolysis and GH-pulse amplification respectively — and are covered in their primary pillars with cross-links here.
How this cluster is organised
The twenty-eight spokes in this pillar divide into three families based on the route by which a compound is proposed to affect sleep. Understanding this taxonomy is essential for interpreting the evidence, because the three families have very different evidence-quality profiles.
Family 1 — Direct sleep-induction candidates. DSIP is the archetype: a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated from rabbit brain venous blood during artificially induced slow-wave sleep by Monnier and Schoenenberger at the University of Basel in the 1970s. The compound was named for its purported ability to induce slow-wave sleep when infused into recipient animals. This family also includes Pinealon and VIP (vasoactive intestinal polypeptide) as putative direct actors on the suprachiasmatic nucleus. Our DSIP deep-dive spoke (6.1) covers the full discovery story, fragmented modern data, and why a 1977 discovery is still at hypothesis stage in 2026.
Family 2 — GH-axis peptides with sleep architecture effects. Growth hormone release is tightly coupled to slow-wave sleep (SWS): the large nocturnal GH pulse occurs during the first SWS episode, and this relationship is bidirectional. Peptides that amplify the GH pulse — MK-677, CJC-1295, Ipamorelin, GHRP-6 — therefore have a plausible, mechanism-anchored rationale for SWS enhancement. The Copinschi et al. (1997, Neuroendocrinology) MK-677 study and the Frieboes et al. (1995, Arch Gen Psychiatry) GHRP-6 study are the primary human data in this cluster. Our MK-677 sleep architecture spoke (6.4) covers this family in depth, specifically as it distinguishes this sleep-specific angle from the broader body-composition and longevity evidence covered in the Pillar 3 MK-677 overview.
Family 3 — Circadian and pineal regulators. The pineal gland synthesises melatonin from serotonin and is the primary biological timekeeper for circadian phase. Epitalon (Ala-Glu-Asp-Gly, a tetrapeptide) is proposed to restore pineal function, elevate melatonin output, and thereby normalise circadian rhythm in older subjects. The Khavinson group at the St. Petersburg Institute of Bioregulation has published extensively on this; the evidence base is real but geographically siloed and largely unreplicated outside Russia. Our Epitalon circadian spoke (6.6) covers this story with explicit caveats about replication status.
DSIP: fifty years of promising and fragmentary
DSIP holds a peculiar status in peptide neuroscience. The original Schoenenberger & Monnier paper (Proc Natl Acad Sci USA, 1977, 74(3):1282–1286) described isolation of a nonapeptide from rabbit brain venous blood sampled during thalamic stimulation-induced sleep, which when infused into recipient rabbits enhanced slow-wave sleep. Graf and Kastin's review (Neurosci Biobehav Rev, 1984) catalogued the first wave of follow-up research, which showed DSIP in blood, CSF, and peripheral tissues of multiple species and suggested roles beyond sleep — including stress modulation, temperature regulation, and analgesia.
The problem that has persisted since the 1980s: DSIP does not have a confirmed high-affinity primary receptor. Unlike melatonin, which acts on well-characterised MT1/MT2 receptors, or GHRH, which signals through the GHRH receptor with defined Kd and downstream cAMP pathway — DSIP's mechanism of action at the molecular level remains genuinely unclear. It may act at opioid receptors, at benzodiazepine binding sites, or through indirect metabolic effects; no consensus exists. Without receptor pharmacology, dose-response relationships cannot be defined in a principled way. Our dedicated DSIP spoke and the DSIP dosing spoke (6.2) address the practical implications of this gap.
Modern human data on DSIP are sparse. Steiger's 2002 review of the hypothalamo-pituitary-adrenocortical system and sleep mentioned DSIP as a compound with plausible sleep-regulatory potential but noted the absence of adequately powered human trials. The Russian and Eastern European literature has the highest volume of modern DSIP work, which creates a parallel to the Epitalon situation — geographically concentrated data that has not been subject to the scrutiny of large independent Western trials. The DSIP research gaps spoke (6.28) documents what is genuinely unknown.
GH-axis peptides and sleep architecture: the most solid evidence in this cluster
The coupling between growth hormone secretion and slow-wave sleep is one of the most replicated findings in human sleep endocrinology. The mechanism: GH-releasing hormone (GHRH) neurons in the hypothalamus co-regulate both sleep onset and pulsatile GH release; blocking GHRH in humans reduces SWS as well as GH secretion (Steiger 2002). This means any compound that amplifies GHRH signalling or directly stimulates GH secretion through the ghrelin receptor (as GH secretagogues including MK-677 do) has a mechanistic pathway to SWS enhancement.
Copinschi et al. (1997) randomised healthy adults to oral MK-677 or placebo and found increases in stage IV and REM sleep, with no change in total sleep time — a profile consistent with GH-pulse amplification specifically during slow-wave sleep rather than sedation. This is important: it distinguishes MK-677's sleep effect from the non-specific sedation produced by benzodiazepines or Z-drugs. Frieboes et al. (1995) showed a similar SWS-promoting effect for GHRP-6, which acts through the same ghrelin receptor pathway. Our MK-677 sleep architecture spoke unpacks the Copinschi data in detail.
The practical limitation: MK-677 is a non-selective ghrelin receptor agonist with significant off-target effects — appetite stimulation, fluid retention, fasting glucose elevation, and potential insulin resistance. Sleep improvement is a real secondary effect, but it comes packaged with a side-effect profile that rules out casual use as a "sleep supplement." Our growth hormone and slow-wave sleep spoke (6.14) covers the underlying endocrinology for researchers wanting to understand the mechanism before considering any compound in this family. The CJC-1295 sleep spoke (6.15) and Ipamorelin sleep spoke (6.20) extend the GH-axis evidence to GHRH analog and selective GHRP contexts respectively.
Epitalon and the pineal clock: a Russian gerontology story
Epitalon (Ala-Glu-Asp-Gly) was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as part of a broader programme of "peptide bioregulators" — short peptides derived from organ extracts, intended to restore age-related organ function. The pineal gland's output of melatonin declines with age; the rationale for Epitalon is that it restores pineal transcriptional activity and thereby raises melatonin levels in older individuals.
The published Khavinson group data (Khavinson et al., Neuroendocrinol Lett, 2001) do show melatonin normalization signals in elderly subjects following Epitalon administration, alongside improvements in circadian rhythm markers. The limitation that any rigorous reader must acknowledge is that these studies have not been independently replicated in peer-reviewed Western trials with pre-registered protocols and industry-independent funding. The effect may be real; the evidence base is not sufficient to establish it as fact by the standards applied to approved therapeutics.
The circadian angle matters clinically because circadian disruption — whether from age-related melatonin decline, shift work, or jet lag — has downstream consequences for immune function, metabolic regulation, and cognitive performance. Peptides that genuinely restore circadian amplitude could be significant. The question of whether Epitalon is such a peptide cannot be answered from existing data alone. Our Epitalon circadian spoke states this clearly and distinguishes the circadian-specific evidence from the broader longevity framing covered in the Pillar 3 Epitalon overview.
Related spoke 6.22 (Pinealon for sleep) covers the companion peptide bioregulator — Lys-Glu-Asp, derived from pineal extract — which has a similar gerontological provenance and a similarly Russian-heavy evidence base. Spoke 6.26 (circadian disruption and peptide approaches) maps the broader landscape of circadian interventions.
Anxiolytic peptides with sleep knock-on effects
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), a synthetic analog of the endogenous immunomodulatory peptide tuftsin, was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It has documented anxiolytic activity in Russian clinical literature, acting through GABA-A receptor modulation and BDNF upregulation rather than through a direct sleep mechanism. The sleep-relevant implication: anxiety is one of the most common contributors to sleep-onset insomnia, and compounds that reduce arousal state without sedation could plausibly improve sleep quality without the dependency risk of benzodiazepines.
This is an indirect effect, not a primary sleep mechanism. Selank does not directly induce sleep; its sleep benefit is conditional on anxiety being the limiting factor. Researchers investigating Selank for sleep contexts should start with the primary Selank spoke in our Cognitive pillar and our dedicated Selank for sleep spoke (6.5), which applies the anxiety-sleep relationship explicitly. Spoke 6.19 (peptides for sleep anxiety) covers the broader literature on anxiolytic peptides and sleep.
Evidence hierarchy across this cluster
The table below grades compounds by the strength of their sleep-specific human evidence. Stage definitions follow the same scale used across all PeptideRadar pillars: (1) In vitro; (2) Rodent; (3) Veterinary/clinical animal; (4) Human Phase I; (5) Human Phase II; (6) Human Phase III; (7) Regulatory approval.
| Compound | Best sleep-specific evidence | Human sleep trial? | Key limitation |
|---|---|---|---|
| MK-677 (Ibutamoren) | Stage 5 — Phase II (Copinschi 1997) | Yes | Side-effect profile limits standalone sleep use; indirect mechanism |
| GHRP-6 | Stage 4–5 — human sleep lab (Frieboes 1995) | Yes (small N) | Small sample; not replicated at scale |
| DSIP | Stage 2–4 — animal + small human studies | Limited, fragmentary | No primary receptor; no Phase III; Eastern European data dominate |
| Epitalon | Stage 4 — human melatonin normalisation (Khavinson group) | Yes (Russian trials) | No independent Western replication; no pre-registered RCT |
| CJC-1295 / Ipamorelin | Stage 2 — rodent GH-pulse studies | No sleep-specific trial | Extrapolated from GH/SWS coupling; not directly studied for sleep |
| Selank | Stage 4–5 — Russian anxiolytic trials | Yes (anxiety, not sleep primary) | Indirect sleep effect; not a primary sleep indication |
| Sermorelin | Stage 4 — GH-axis trials | No sleep-specific trial | Same GH/SWS rationale as CJC-1295; less MK-677-equivalent data |
| VIP | Stage 2 — animal circadian clock | No | SCN mechanism well-evidenced in animals; human data absent |
The honest takeaway: this cluster has thinner human evidence than any other PeptideRadar pillar. The strongest data — Copinschi 1997 on MK-677, Frieboes 1995 on GHRP-6 — are small, now nearly thirty years old, and have not been replicated in large, pre-registered trials. Researchers approaching this cluster should weight mechanism plausibility highly (especially for GH-axis compounds) while maintaining proportionately high skepticism about magnitude of effect. Our best peptides for sleep roundup spoke (6.17) applies this hierarchy to a practical comparison across all main candidates.
The spoke articles, by sub-topic
DSIP sub-cluster
The hub is the DSIP deep-dive spoke (6.1), covering the Monnier/Schoenenberger discovery, the structure-activity story, the fragmented receptor pharmacology, and the modern data landscape. Supporting spokes: DSIP dosing (6.2), DSIP side effects (6.18), DSIP research gaps (6.28), and stacking DSIP with CJC-1295 (6.25). Spoke 6.11 (melatonin vs DSIP) provides the most practically useful comparison for researchers evaluating sleep interventions.
GH-axis sleep sub-cluster
Spoke 6.4 (MK-677 sleep architecture) is the primary evidence hub for this family. Spoke 6.14 (growth hormone and slow-wave sleep) provides the mechanistic foundation. Spokes 6.15 (CJC-1295 and sleep quality), 6.16 (sermorelin and sleep), 6.20 (Ipamorelin and sleep), 6.27 (GHRP class and sleep), and 6.9 (peptides for deep sleep) complete this sub-cluster.
Circadian and pineal sub-cluster
Spoke 6.6 (Epitalon and circadian rhythm) is the primary hub. Spoke 6.22 (Pinealon for sleep), spoke 6.12 (VIP peptide and circadian regulation), spoke 6.26 (circadian disruption and peptide approaches), spoke 6.8 (peptides for jet lag), and spoke 6.10 (peptides for shift workers) cover specific circadian-disruption contexts.
Anxiolytic and sleep-adjacent spokes
Spoke 6.5 (Selank for sleep), spoke 6.19 (peptides for sleep-anxiety comorbidity), spoke 6.3 (peptides for insomnia), and spoke 6.7 (Thymalin and sleep-recovery) cover the anxiety-sleep interface and the Russian bioregulator adjacent to Epitalon.
Population-specific and comparison spokes
Spokes 6.23 (peptides for menopause-related sleep disruption), 6.24 (peptides for andropause-related sleep changes), 6.13 (peptides and sleep apnoea research), and 6.21 (peptides and REM sleep) address specific research populations and sleep-stage-specific questions.
Cross-cluster bridges
This pillar shares mechanistic territory with three adjacent clusters. The Cognitive & Nootropic pillar (Pillar 2) covers Selank and Semax in their primary anxiolytic and cognitive-enhancement contexts; the sleep knock-on effects are secondary. Researchers investigating anxiety-driven insomnia should read that pillar before arriving at the sleep-specific spokes here.
The Longevity & GH Axis pillar (Pillar 3) covers the primary pharmacology of MK-677, CJC-1295, Ipamorelin, Sermorelin, and Epitalon in their longevity and body-composition contexts. The sleep spokes here are intentionally sleep-specific and cross-link to the Pillar 3 overviews to avoid duplication.
The Sleep pillar has a weaker case for a Weight/Metabolic bridge than most — disrupted sleep does impair metabolic function and amplifies GLP-1 drug side effects — but this is an indirect relationship and is addressed in specific spokes rather than as a pillar-to-pillar bridge at this level.